BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 17559054)

  • 1. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The choice of sample size: a mixed Bayesian / frequentist approach.
    Pezeshk H; Nematollahi N; Maroufy V; Gittins J
    Stat Methods Med Res; 2009 Apr; 18(2):183-94. PubMed ID: 18445695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
    Shao Y; Mukhi V; Goldberg JD
    Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust Bayesian sample size determination in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
    Zohar S; Teramukai S; Zhou Y
    Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
    Gordon Lan KK; Wittes JT
    Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA; van der Tweel I
    Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of four sequential methods allowing for early stopping of comparative clinical trials.
    Sebille V; Bellissant E
    Clin Sci (Lond); 2000 May; 98(5):569-78. PubMed ID: 10781388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian sample size for exploratory clinical trials incorporating historical data.
    Whitehead J; Valdés-Márquez E; Johnson P; Graham G
    Stat Med; 2008 Jun; 27(13):2307-27. PubMed ID: 18069728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
    Atkinson AC; Biswas A
    Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.